|
RBM18 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.05020453339466E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.03819997043786E-09 |
| Normal-vs-Stage2 |
3.018300E-04 |
| Normal-vs-Stage3 |
1.89069981892942E-10 |
| Normal-vs-Stage4 |
3.89920318255577E-11 |
| Stage1-vs-Stage2 |
3.912000E-01 |
| Stage1-vs-Stage3 |
7.565800E-02 |
| Stage1-vs-Stage4 |
7.943700E-03 |
| Stage2-vs-Stage3 |
6.598100E-02 |
| Stage2-vs-Stage4 |
1.132230E-02 |
| Stage3-vs-Stage4 |
2.544200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.68809452264441E-12 |
| Normal-vs-AfricanAmerican |
1.784230E-04 |
| Normal-vs-Asian |
3.35620000013748E-07 |
| Caucasian-vs-AfricanAmerican |
5.155600E-01 |
| Caucasian-vs-Asian |
7.642200E-01 |
| AfricanAmerican-vs-Asian |
6.986600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.64409597047666E-11 |
| Normal-vs-Female |
7.58189955263333E-10 |
| Male-vs-Female |
8.078400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.74379999831709E-08 |
| Normal-vs-Age(41-60Yrs) |
4.03539979210166E-10 |
| Normal-vs-Age(61-80Yrs) |
1.17940002208883E-09 |
| Normal-vs-Age(81-100Yrs) |
4.844800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.468600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.226800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.898400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.190400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.012400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.436800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.208200E-02 |
| Classical-VS-Follicular |
3.539600E-01 |
| Classical-VS-Other |
3.687400E-01 |
| Classical-VS-Normal |
1.03239972126801E-10 |
| Tall-VS-Follicular |
2.750400E-02 |
| Tall-VS-Other |
9.952600E-01 |
| Tall-VS-Normal |
1.63879999570682E-08 |
| Follicular-VS-Other |
3.189800E-01 |
| Follicular-VS-Normal |
5.7466000000006E-05 |
| Other-VS-Normal |
1.081330E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.9148999576617E-09 |
| Normal-vs-N1 |
2.80990009038362E-10 |
| N0-vs-N1 |
2.680400E-02 |
|
|
